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SOMATOSTATIN FOR BLEEDING OESOPHAGITIS
OR ULCERATION AFTER SCLEROTHERAPY FOR
OESOPHAGEAL VARICES
ABSTRACT
Jenkins, S.A., Shields, R., Jaser, N., Ellenbogen, S., Makin, C., Naylor, E.,
Newstead, M., Baxter, J.N. (1991) The Management of gastrointestinal haemorr-
hage by somatostatin after apparently successful endoscopic injection sclerotherapy
for bleeding oesophageal varices. Journal of Hepatology; 12: 296-301.
Twenty-two patients who experienced a severe haemorrhage from either oesophagi-
tis (n 8) or ulcers (n 14) following injection sclerotherapy of their oesophageal
varices were treated with intravenous administration of somatostatin (250 g/h).
Somatostatin was effective in controlling haemorrhage and preventing rebleeding in
all eight patients bleeding from oesophagitis and in 12 of the 14 patients bleeding
from oesophageal ulcers. In two patients with ulcers, haemorrhage persisted despite
two periods of concominant balloon tamponade and somatostatin infusion and
bleeding was eventually controlled by repeated hourly bolus injections of the
hormone for 24 h superimposed on the continuous infusion. The results of this study
suggest that somatostatin is an effective and safe treatment for the control of
bleeding from either oesophagitis or ulcers following injection sclerotherapy of
oesophageal varices.HPB INTERNATIONAL 285
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Mr Jenkins and colleagues have produced the results of another careful study from
their Unit on the value of Somatostatin in managing upper gastrointestinal
haemorrhage associated with portal hypertension and oesophageal varices. This
adds to the existing literature on the value of this therapeutic modality1. They have
shown previously the value of this drug in the management of acute variceal
bleeding and although the exact mechanism of action is unknown, it seemed logical
to extend studies into patients suffering from the haemorrhagic complications of
injection sclerotherapy.
They found Somatostatin controlled recurrent major haemorrhage after oeso-
phageal bleeding had been arrested initially by injection sclerotherapy. Infusion of
the drug successfully treated all their patients who were bleeding from oeosophagi-
tis and most of the patients bleeding from oeosophageal ulcers. For those in whom
haemorrhage continued then additional bolus injections were successful.
Apart from pharmacological and injection sclerotherapy techniques, alternative
ways of treating acute variceal haemorrhage involve surgical techniques: oesopha-
gogastric disconnection and re-anastomosis using the staple gun with or without
gastric devascularisation, acute portal-systemic decompression shunting and liver
transplantation. It is unlikely that liver transplantation would be entertained in this
situation on a regular basis but acute surgery certainly must. Despite a bad press a
few years ago, emergency portacaval shunting, especially small diameter shunts,
still has its advocates
2 but injection sclerotherapy is the number one management
method in most centres. However it has been shown that if two attempts at
controlling bleeding by endoscopic sclerotherapy fail the mortality is unacceptably
high. Two independent groups have shown that in this situation a surgical approach
must be considered3’4.
It is probably incorrect for the authors of this paper to say that emergency
surgery in these patients carries a "prohibitively high mortality and morbidity". In a
carefully controlled prospective study of the results of sclerotherapy compared with
oesophageal transection in a group of patients selected for the severity of their
disease they all failed to respond to conservative measures the mortality and
morbidity were comparable. Furthermore the studies showed that later rebleeding
was perhaps less frequent and certainly less severe in the transection group than
following sclerotherapy4. Others have reported transection may offer better results
than sclerotherapy especially in lower risk groups5.
Other studies have shown that rebleeding following staple transection is often
due to oesophageal ulceration at the site of the staples which can be readily
controlled and treated with Omeprazole7.
Patients presenting with bleeding oesophageal varices due to liver disease
induced portal hypertension must nowadays be considered for eventual liver
transplantation. In those who may become candidates then any method of treating
the acute problem should not jeopardise this definitive procedure. However the
problems associated with carrying out a liver transplant following previous abdomi-
nal surgery have probably been overstated. Although the operation may be more
taxing to the surgeon there is no recent objective evidence of any increased
morbidity or mortality.286 HPB INTERNATIONAL
Many patients are, of course, not suitable for transplantation and for these it is
essential to control the bleeding using a safe technique which will further confer
freedom from rebleeding with maximum prolongation of life. It remains to be seen
if this will be repeated sclerotherapy, portal decompression- total or selective
or oesophageal transection and devascularisation or pharmacological therapy.
This study clearly demonstrates that the latter concept is viable. However there
are cost considerations which must be taken into account. The doses used in this
study would cost a British hospital in the order of a thousand pounds for a four day
course and additional treatments may be needed. By comparison, Omeprazole
costs a little over 10 a week. Surgery is of course more difficult to cost.
This reports an important study with a very positive outcome but it is essential
now to investigate further whether the conclusion "that Somatostatin is a safe and
effective treatment for post-injection sclerotherapy bleeding from ulcers or oeso-
phagitis" can withstand the rigours of a prospective controlled trial comparing its
cost effectiveness with other therapeutic modalities. Clinicians involved in the
management of this very difficult group of patients, and I suspect the pharmaceuti-
cal industry, will await the results of such studies with great interest.
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